Figure 1.
Schematic representation of mechanisms blocking androgen and estrogen actions. Most of the current drugs used to treat steroid-dependent tumors either: 1) block the biosynthesis of steroid hormones (aromatase
inhibitors) or 2) prevent transcriptional activation of steroid responsive genes by inhibiting the binding of endogenous steroids
to their intracellular receptors (androgen receptor (AR) or estrogen receptor (ER) antagonists). Megalin has been identified
as an endocytic receptor for the cellular uptake of steroid/sex hormone binding globulin (SHBG) complexes (7). Development of megalin antagonists, that block the entry of steroids into cells, may serve as an alternative or synergistic
treatment to presently available therapeutics.